Mainz Biomed N.V.
Robert Koch Strasse 50
55129 Mainz
Germany
January 24, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Re: | Mainz Biomed N.V. |
Registration Statement on Form F-1
File No. 333-262294
Ladies and Gentlemen:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective as of 5:00pm Eastern Time on Tuesday, January 25, 2022, or as soon thereafter as practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The undersigned respectfully requests that it be notified of the effectiveness of the above-referenced Registration Statement by telephone call to our counsel, Ortoli Rosenstadt LLP, by calling Tim Dockery at (212) 829-8946. The Company hereby authorizes Mr. Dockery to orally modify or withdraw this request for acceleration.
Very truly yours,
MAINZ BIOMED N.V.
| By: | /s/ William J. Caragol | |
| Name: | William J. Caragol | |
| Title: | Chief Financial Officer |
